TACSTD2 and neoplasm: To circumvent the potential for on-target off-tumor toxicities leading to treatment failure, HARPOON Therapeutics has developed a Trop2-targeted ProTriTACTM (Protease-activated Tri-specific T cell Activating Construct), a prodrug designed for selective activation within tumor tissues.